Medicine and Dentistry
Adverse Event
57%
Age
15%
Alpha Adrenergic Receptor Blocking Agent
20%
Analysis
15%
Anxiety
6%
Arterial Embolization
23%
Assessment
9%
Bladder
14%
Cancer Risk Factor
7%
Cell Therapy
8%
Chemotherapy
13%
Child
13%
Chronic Pelvic Pain Syndrome
9%
Clear Cell Renal Cell Carcinoma
13%
Combination Therapy
41%
Complication
12%
Computer Assisted Tomography
7%
Continence
7%
Desmopressin
13%
Development
8%
Diagnosis
10%
Digital Rectal Examination
7%
Diseases
12%
Enucleation
5%
Erectile Dysfunction
8%
Evaluation Study
6%
Experience
8%
Extracorporeal Shockwave Therapy
6%
Follow up
30%
Gleason Score
5%
Health
19%
Health Care Cost
9%
In Vitro
5%
Incidence
11%
Injury
5%
Inpatient
22%
International Prostate Symptom Score
23%
Language
12%
Lesion
5%
Lithotripsy
6%
Lower Urinary Tract Symptom
47%
Male
10%
Malignant Neoplasm
13%
Man
89%
Meta-Analysis
21%
Metabolic Syndrome
5%
Minimally Invasive Procedure
7%
Monotherapy
9%
Naftopidil
8%
Neoplasm
9%
Nephropathy
5%
Nephroureterectomy
6%
Nocturia
6%
Obstetric Delivery
5%
Obstruction
5%
Odds Ratio
5%
Overall Survival
7%
Parasympatholytic
7%
Partial Nephrectomy
8%
Patient
100%
Pelvis
9%
Pembrolizumab
5%
Platelet-Activating Factor
5%
Postoperative Complication
5%
Prognostic Factor
13%
Prostate
16%
Prostate Cancer
59%
Prostate Hypertrophy
49%
Prostate Specific Antigen
32%
Prostatectomy
37%
Prostatitis
13%
Quality of Life
31%
Random Effects Model
9%
Randomized Controlled Trial
36%
Recurrent Disease
7%
Retreatment
9%
Robot-Assisted Prostatectomy
20%
Screening
7%
Sedation
13%
Serum
12%
Shock (Circulatory)
6%
Silodosin
9%
Single Drug Dose
6%
Specimen
6%
Steroid 5alpha Reductase Inhibitor
5%
Stone
14%
Surgery
25%
Symptom
61%
Systematic Review
44%
Tamsulosin
5%
Therapeutic Procedure
85%
Tissues
7%
Transitional Cell Carcinoma
8%
Transrectal Ultrasonography
15%
Transurethral Resection
34%
Urinary System
10%
Urolithiasis
10%
Water
12%
Nursing and Health Professions
Adverse Event
22%
Analysis
5%
Arterial Embolization
10%
Chronic Prostatitis
6%
Confidence Interval
37%
Data Base
8%
Device Material
5%
Diagnosis
5%
Follow up
8%
Gemcitabine
8%
Inpatient
5%
Malignant Neoplasm
5%
Man
23%
Meta Analysis
14%
Neoplasm
5%
Non Muscle Invasive Bladder Cancer
6%
Patient
10%
Placebo
5%
Procedures
13%
Prostate Cancer
25%
Prostate Hypertrophy
5%
Prostate Specific Antigen
10%
Prostatectomy
8%
Publication
5%
Quality of Life
12%
Robotics
9%
Sexual Dysfunction
6%
Standard
7%
Symptom
18%
Systematic Review
21%
Time
10%
Transurethral Resection
7%